noodls browser compatibility check

The security settings of your browser are blocking the execution of scripts.

To use noodls, javascript support must be enabled. Please change your browser's security settings to enable javascript.

If you have changed your browser's security settings, you can click here.

related announcements

News

NMMA - National Marine[...]

Bill Introduced in U.S. House of Representatives to Reduce Taxes on[...]
Idaho Department of Fish and Game

Applications for spring turkey controlled hunts open Feb. 1
Iowa Farm Bureau Federation

Marketing Insights 1-28-2026

Healthcare

Crinetics Pharmaceuticals Inc.

01/26/2026 | Press release | Distributed by Public on 01/26/2026 08:07

Management Change/Compensation (Form 8-K)

Item 5.02 Departure of Directors or Certain Officers; Election of Directors, Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On January 20, 2026, the board of directors of Crinetics Pharmaceuticals, Inc. (the "Company") approved a change in title and responsibilities for Jeff Knight, from Chief Operating Officer to Chief Development and Operating Officer, effective January 2, 2026.

The change in title reflects Mr. Knight's responsibilities and scope of duties.

There were no changes to Mr. Knights's compensation arrangements, as described in the Company's definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 23, 2025 (the "2025 Proxy Statement"), in connection with this title change. There are no arrangements or understandings between Mr. Knight and any other person pursuant to which he was selected as Chief Development and Operating Officer, there are no family relationships between Mr. Knight and any director or executive officer of the Company, and there are no reportable family relationships or related party transactions (as defined in Item 404(a) of Regulation S-K) involving Mr. Knight and the Company. A description of Mr. Knight's business experience is contained in the 2025 Proxy Statement, which description is incorporated herein by reference.

Crinetics Pharmaceuticals Inc. published this content on January 26, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on January 26, 2026 at 14:07 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]